HER-2 positive

This study suggests that selected patients with de novo mBC and locoregional oligoprogression can benefit from breast surgery while maintaining the same systemic treatment, particularly in the setting of HER2-positive disease or a pre-oligoprogression PFS >1 year.

P3, N=738, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

Interventions to prevent or treat CRCI are needed to improve the long-term quality of life of these patients treated with chemotherapy. ClinicalTrials.gov Identifier: NCT01272037.

These data add to the current view that nanobody selection for CAR design remains subject to extensive side-by-side screening. Still, superior cytotoxicity across multiple solid tumor cell lines-determined using in vitro assays evaluating activation, cytokine secretion, and target cell-specific killing-led to selection and further characterization of a lead nanoCAR 1R59b, showing tumor control in an in vivo xenograft model, providing a promising HER2 nanoCAR for further (pre)clinical investigation.

Pyrotinib showed good antitumor activity in the treatment of patients with HER2-positive advanced breast cancer and displayed a degree of efficacy in patients with brain metastases. The main adverse reaction was diarrhea, which was mostly low to moderate in severity, and the incidence of high-grade AEs was generally low, with controllable toxicity.

Conversely, patients within the high-risk category are more likely to benefit from NAC and should be prioritized for this treatment to maximize survival gains. Prospective integration of targeted therapy data will refine these precision oncology tools.

Survival sequential analysis highlights subtype-specific surveillance priorities: intensified monitoring within 3 years for TNBC, focused follow-up at 7-8 years for HER2-positive subtype, and extended tracking for Luminal subtypes. Both nomograms and the RSF model demonstrated robust predictive performance, providing theoretical and practical tools for precision prognosis management in breast cancer.

All enrolled patients received the full treatment protocol consisting of anthracycline followed by 12 months of trastuzumab alone or with pertuzumab. The highest risk was observed when both elevated hs-Tn I (≥82 ng/L after four cycles of anti-HER2 agents) and elevated hs-CRP (after four cycles of anthracyclines) were present. The interaction between both hs-Tn I and hs-CRP demonstrates significant predictive value for cardiotoxicity risk related to HER2+ breast cancer treatment.

Conversely, T-DXd administered due to the presence of HER2-low showed excellent effectiveness. Performing a re-biopsy is crucial due to the possible loss of estrogen receptors, which would require a change in therapeutic strategy no longer based on endocrine therapy. In cases that remain luminal, knowledge of the mutational profile may help to offer patients novel targeted treatments.

P2, N=13, Terminated, Spanish Breast Cancer Research Group | Trial completion date: Aug 2026 --> May 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2026 --> May 2025; The study was closed early due to safety concerns and an unfavorable benefit-risk balance. Unexpected high neutropenia rates required a costly sub-study, which was not feasible, forcing the sponsor to terminate the trial prematurely.

P1, N=168, Completed, AbbVie | Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Jun 2025 --> Sep 2025

Patients with metastatic HR+HER2- IBC demonstrated a shorter time on treatment suggesting shorter duration of response on CDKI + HT, which is markedly inferior to reported data for non-IBC patients from phase III trials.